XBP1s expression level may be one of the key players in tamoxifen-resistant breast cancer, while IRE1, the upstream nuclease which mediates the splicing of XBP1 pre-mRNA, may be a potential target for reducing resistance. Here, XBP1 is linked to breast carcinoma.